A Multicenter, Prospective, Double-Blind, Randomized, Placebo-Controlled, 6-Month Study to Establish the Effect of Fluvastatin 40 mg (b.i.d.) [twice per day] in the Prevention of the Development of Vascular Graft Disease in de Novo Renal Transplant Patients.
Phase of Trial: Phase IV
Latest Information Update: 28 Feb 2017
At a glance
- Drugs Fluvastatin (Primary)
- Indications Vascular disorders
- Focus Therapeutic Use
- Sponsors Novartis
- 03 Jan 2008 New trial record.